Baird raised the firm’s price target on Bio-Techne (TECH) to $70 from $61 and keeps a Neutral rating on the shares. The firm updated its model following Q2 results and said they would be buyers of the shares on pullbacks.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH:
- Bio-Techne Earnings Call Balances Headwinds With Margin Gains
- Bio-Techne: Near-Term Resilience and Margin Expansion Support Accelerating Growth and Buy Rating Into 2027
- Bio-Techne price target raised to $80 from $70 at Citi
- Bio-Techne posts stable Q2 results with margin gains
- Bio-Techne reports Q2 adjusted EPS 46c, consensus 43c